Go Pro
OTCMKTS:ARTH

Arch Therapeutics (ARTH) Stock Price, News & Analysis

Arch Therapeutics logo
$0.16 0.00 (0.00%)
As of 08/4/2026

About Arch Therapeutics Stock (OTCMKTS:ARTH)

Advanced

Key Stats

Today's Range
$0.16
$0.16
50-Day Range
$0.16
$0.16
52-Week Range
$0.16
$1.57
Volume
N/A
Average Volume
4,068 shs
Market Capitalization
$762.51 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Arch Therapeutics, Inc. (OTCMKTS: ARTH) is a development‐stage medical device company focused on applying its proprietary synthetic self‐assembling peptide technology to hemostasis, sealant and antimicrobial applications. Its platform is designed to rapidly form protective barriers in wet surgical and trauma environments without requiring external energy, with the goal of improving patient outcomes and reducing procedure times.

The company’s lead product candidates utilize its AC5™ formulation, which is being evaluated for a range of clinical indications including bleeding control during open and minimally invasive surgeries, emergency trauma care and interventional radiology procedures. Arch is also exploring advanced applications of its peptide technology in tissue regeneration and infection prevention.

Headquartered in Framingham, Massachusetts, the company primarily operates within the United States while pursuing regulatory approvals in key international markets. Arch collaborates with clinical partners and contract manufacturers to advance its pipeline through preclinical and clinical studies, as well as to scale for potential commercialization.

Established in the late 2000s, Arch has evolved from a research‐driven enterprise to a product development organization. Its leadership team comprises professionals with backgrounds in medical device engineering, clinical research and regulatory affairs, positioning the company to navigate the complexities of developing next‐generation surgical and trauma care solutions.

AI Generated. May Contain Errors.

Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARTH Stock News Headlines

Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
Arch Therapeutics, Inc. (ARTH)
See More Headlines

ARTH Stock Analysis - Frequently Asked Questions

Arch Therapeutics' stock was trading at $0.1608 on May 30, 2026. Since then, ARTH shares have increased by 0.0% and is now trading at $0.1608.

Arch Therapeutics, Inc. (OTCMKTS:ARTH) posted its quarterly earnings data on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01.

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arch Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), GE Aerospace (GE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
7/23/2020
Today
8/05/2026
Fiscal Year End
9/30/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
OTCMKTS:ARTH
Previous Symbol
NASDAQ:ARTH
CIK
1537561
Fax
N/A
Employees
10
Year Founded
2006

Profitability

EPS (Trailing Twelve Months)
($2.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.98 million
Net Margins
-8,257.70%
Pretax Margin
-8,257.70%
Return on Equity
N/A
Return on Assets
-730.22%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.10
Quick Ratio
0.01

Sales & Book Value

Annual Sales
$80 thousand
Price / Sales
9.53
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.43) per share
Price / Book
-0.07

Miscellaneous

Outstanding Shares
4,742,000
Free Float
4,529,000
Market Cap
$762.51 thousand
Optionable
Not Optionable
Beta
4.02

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (OTCMKTS:ARTH) was last updated on 8/5/2026 by MarketBeat.com Staff.
From Our Partners